Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia

Leuk Lymphoma. 2020 Dec;61(12):2990-2994. doi: 10.1080/10428194.2020.1786553. Epub 2020 Jul 4.

Authors

Colin D Godwin^{1

2}, Olivia M Bates¹, Sae Rin Jean³, George S Laszlo¹, Eliotte E Garling¹, Mary E Beddoe¹, Michael H Cardone³, Roland B Walter^{1

2

4

5}

Affiliations

¹ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
² Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
³ Eutropics Pharmaceuticals, Inc, Cambridge, MA, USA.
⁴ Department of Pathology, University of Washington, Seattle, WA, USA.
⁵ Department of Epidemiology, University of Washington, Seattle, WA, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Apoptosis
Apoptosis Regulatory Proteins
Calicheamicins
Humans
Immunoconjugates* / therapeutic use
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Proto-Oncogene Proteins c-bcl-2 / genetics

Substances

Apoptosis Regulatory Proteins
Calicheamicins
Immunoconjugates
Proto-Oncogene Proteins c-bcl-2

Grants and funding